Have you attempted do to a Neurontin Taper only to suffer symptoms that interfere with life? Do you need help to Get Off Neurontin and Stay Off Neurontin? Do you know how to Taper Off Neurontin in order to control the Neurontin Withdrawal Symptoms? Our holistic approach to Neurontin Withdrawal is unmatched and why our at-home program has reach 78 countries over the last 15 years. It is important to Wean off Neurontin to minimize the challenging symptoms, but we place our focus on support you as you Taper off Neurotonin slowly. Neurontin Withdrawal can resemble the benzodiazepine withdrawal syndrome which is why Tapering Neurontin while calming the nervous system has proven highly effective. We know that if you need Neurontin Withdrawal Help our nonprofit is a proven, at-home method to Get off Neurontin and regain your life. CONTACT us for a Free Consultation on a proper Neurontin Taper.
SUCCESSFUL CHOICES YOU CAN MAKE RIGHT NOW
Our Neurontin weaning program is a slow taper that allows you to safely step down from Neurontin under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Neurontin until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Neurontin and support well-being*
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Neurontin Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Neurontin alone, work with our Prescription Drug Experts.
Imagine being Free of Neurontin Dependency
- Proven Program completed In-Home with Expert Guidance
- Slowly Wean Neurontin
- All-Natural Nutraceuticals to help Ease Neurontin Withdrawal
- Professional information on interactions
- Free Mentoring on our 24/7 private Discussion Board
- Free Assessment Upon Starting our Program (a $400 value)
Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program *USA & Canada Only
EXPERIENCE and TEAMWORK
using a Natural Approach
Neurontin History and Information
Neurontin (Gabapentin) was discovered by Gerhard Satzinger for Parke-Davis’ German Labs while searching for a drug molecule that targeted GABA. GABA was known to be the targeted neurotransmitter for benzodiazepines but since it could not cross the blood brain barrier, Satzinger synthesized Gabapentin (Neurontin) by incorporating GABA into a ring that could pass from blood to brain. Pfizer obtained Gabapentin in 2000. The drug was initially expected to make no more than $500,000 but by 2001 sales exceeded $1.2 billion.
Neurontin affects GABA, the most calming neurotransmitter of the human body and post marketing reports have shown there is a potential of abuse, dependency and withdrawal symptoms. Pfizer does recognize that Gabapentin (Neurontin) can cause withdrawal symptoms and states, “ There are rare postmarketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses of gabapentin used to treat illnesses for which the drug is not approved. Such symptoms included agitation, disorientation and confusion after suddenly discontinuing gabapentin that resolved after restarting gabapentin.”
The demand for Neurontin was limited since it was only approved for partial seizures, and Parke-Davis defrauded the government by encouraging doctors to write prescriptions for Neurontin for uses other than approved (off-label) and then seek Medicaid reimbursement. While doctors can prescribe a drug for off-label uses, a drug company is not allowed to promote or market a prescription drug for a medical condition without first proving it is safe and effective to the FDA. The fine that Pfizer paid was the second largest in U.S. history.
Because Neurontin can cause feelings of calm, relaxation and euphoria, both tolerance to the drug and withdrawal symptoms can occur. Pregabalin is the EU version of Neurontin and in 2010 Pregalalin was listed as a new recreational psychoactive substance.
It is recommended to slowly taper Neurontin to minimize withdrawal symptoms. Neurontin is often given for Benzodiazepine withdrawal and must be tapered in a similar manner. Our nonprofit has been helping people safely withdraw from Neurontin for 15 years. We can also help you.
Neurontin Withdrawal Symptoms, Side Effects, Adverse Reactions
NEURONTIN WITHDRAWAL SYMPTOMS MAY INCLUDE:
drowsiness, dizziness, dry mouth, blurred vision, constipation, weight gain, or trouble urinating, myocardial infarction, arrhythmia, hypotension, hypertension, palpitation, tachycardia, coma, seizures, hallucinations; delusions, confused states; disorientation, incoordination, tremors, peripheral neuropathy, abnormal involuntary movements, tardive dyskinesia, dysarthria, disturbed concentration, anxiety, insomnia, restlessness, nightmares, drowsiness, dizziness, weakness, fatigue, headache, syndrome of inappropriate ADH secretion, tinnitus, hyperpyrexia, urinary retention, dilation of urinary tract, constipation, blurred vision, increased ocular pressure, skin rash, urticarial, edema of face and tongue, bone marrow depression, nausea, vomiting, anorexia, stomatitis; peculiar taste, diarrhea, black tongue, testicular swelling, breast enlargement – female, increased or decreased libido, impotence, elevation and lowering of blood sugar levels, alopecia, weight gain or loss, urinary frequency, increased perspiration
NEURONTIN SIDE EFFECTS MAY INCLUDE:
blurry vision or double vision, dizziness, headache, uncontrollable shaking of a body part, rash, anxiety, memory problems, uncontrollable eye movements, fatigue, coordination problems, nausea, vomiting, diarrhea, dry mouth, heartburn, increased appetite and weight gain, fever, pain in the ears, back and joints, itchy, red dyes, flu-like symptoms, suicidal thoughts or behavior, acting on risky impulses, panic attacks, aggressive and violent behavior, mania (abnormally excited, frenzied mood)
NEURONTIN ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: suicidal ideation, teratogenesis, anaphylactoid reactions, Stevens-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS, angioedema, erythema multiforme, rhabdomyolysis
Moderate: ataxia, peripheral edema, nystagmus, hostility, blurred vision, constipation, amblyopia, impaired cognition, amnesia, dysarthria, peripheral vasodilation, dystonic reaction, conjunctivitis, hyperglycemia, withdrawal, tolerance, choreoathetosis, depression, involuntary movements, confusion, memory impairment, hepatitis, dyspnea, hypertension, dehydration, jaundice, hyponatremia, eosinophilia
Mild: dizziness, drowsiness, headache,fatigue, asthenia, nausea, vomiting, insomnia, tremor, diarrhea, diplopia, weight gain, lethargy, libido decrease, back pain, irritability, vertigo, appetite stimulation, dyspepsia, anorexia, xerostomia, flatulence, cough, rhinitis, infection, pharyngitis, rash, emotional lability, restlessness, fever, skin irritation
NEURONTIN CONTRAINDICATIONS: per PDR:
Depression, suicidal ideation
In January 2008, the FDA alerted healthcare professionals of an increased risk of suicidal ideation and behavior in patients receiving anticonvulsants to treat epilepsy, psychiatric disorders, or other conditions (e.g., migraine, neuropathic pain). This alert followed an initial request by the FDA in March 2005 for manufacturers of marketed anticonvulsants to provide data from existing controlled clinical trials for analysis. Prior to this request, preliminary evidence had suggested a possible link between anticonvulsant use and suicidality. The primary analysis consisted of 199 placebo-controlled clinical studies with a total of 27,863 patients in drug treatment groups and 16,029 patients in placebo groups (>= 5 years of age). There were 4 completed suicides among patients in drug treatment groups versus none in the placebo groups. Patients receiving anticonvulsants had approximately twice the risk of suicidal behavior or ideation as patients receiving placebo (0.43% vs. 0.24%, respectively; RR 1.8, 95% CI: 1.2—2.7). The relative risk for suicidality was higher in patients with epilepsy compared to those with other conditions; however, the absolute risk differences were similar in trials for epilepsy and psychiatric indications. Age was not a determining factor. The increased risk of suicidal ideation and behavior was observed between 1 and 24 weeks after therapy initiation. However, a longer duration of therapy should not preclude the possibility of an association to the drug since most studies included in the analysis did not continue beyond 24 weeks. Data were analyzed from drugs with adequately designed clinical trials including carbamazepine, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, valproate, and zonisamide. However, this is considered to be a class effect. All patients beginning treatment with anticonvulsants or currently receiving such treatment should be closely monitored for emerging or worsening depression or suicidal thoughts/behavior. Patients and caregivers should be informed of the increased risk of suicidal thoughts and behaviors and should be advised to immediately report the emergence or worsening of depression, the emergence of suicidal thoughts or behavior, thoughts of self-harm, or other unusual changes in mood or behavior. Anticonvulsants should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose.
Neurontin References and Information
Neurontin (Gabapentin) is widely utilized currently for the chronic treatment of recalcitrant migraines, bipolar illness, pain, and epilepsy. It has a wide therapeutic index with few side effects and drug interactions, is not hepatically metabolized, and is excreted by the kidneys. Past reports have suggested that some withdrawal symptoms can present after 1-2 days upon abrupt discontinuation of Neurontin (Gabapentin) after chronic use within young to middle-aged patients. These symptoms mimic that of alcohol and benzodiazepine withdrawal purportedly due to a similar mechanism of action. Unique to this case is that this geriatric patient developed debilitating withdrawal symptoms after a gradual, week-long taper of Neurontin (Gabapentin) along with flu-like symptoms. It is proposed herein that a Neurontin (Gabapentin) taper should follow a course similar to that of a benzodiazepine taper -- slowly and over a period of weeks to months.
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
* Testimonial results may vary person to person.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.
*This program is not meant to cure or prevent any disease or illness.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..